1. |
IARC. GLOBOCAN 2012: Estimated cancer incidenee, mortality and prevalence worldwide in 2012.(2013-12-1) [2014-1-20]. http://globocan.iarc.Fr/Default.aspx.
|
2. |
芦海亮, 王跃花, 王丽霞, 等.乳腺癌分子分型与临床病理特征的相关性研究.中国药物与临床, 2013, 13(4): 498-499.
|
3. |
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 2011, 121(7): 2750-2767.
|
4. |
Steward L, Conant L, Gao F, et al. Predictive factors and patterns of recurrence in patients with triple negative breast cancer. Ann Surg Oncol, 2014, 21(7): 2165-2171.
|
5. |
Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109(1): 25-32.
|
6. |
Gasparini P, Fassan M, Cascione L, et al. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PLoS One, 2014, 9(2): e88525.
|
7. |
Tang Y, Zhu L, Li Y, et al. Overexpression of epithelial growth factor receptor(EGFR) predicts better response to neo-adjuvant chemo-therapy in patients with triple-negative breast cancer. J Transl Med, 2012, 10(Suppl 1): S4.
|
8. |
Koo JS, Jung W. Clinicopathlogic and immunohistochemical chara-cteristics of triple negative invasive lobular carcinoma. Yonsei Med J, 2011, 52(1): 89-97.
|
9. |
Nogi H, Kobayashi T, Suzuki M, et al. EGFR as paradoxical predi-ctor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep, 2009, 21(2): 413-417.
|
10. |
Rydén L, Jirström K, Haglund M, et al. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat, 2010, 120(2): 491-498.
|
11. |
Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer:molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat, 2008, 111(1): 27-44.
|
12. |
Tawfik O, Davis K, Kimler BF, et al. Clinicopathological characteris-tics of triple-negative invasive mammary carcinomas in African-American versus Caucasian women. Ann Clin Lab Sci, 2010, 40(4): 315-323.
|
13. |
Wang XZ, Liu Q, Sun JJ, et al. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification. Genet Mol Res, 2015, 14(2): 4282-4290.
|
14. |
Tao JJ, Castel P, Radosevic-Robin N, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal, 2014, 7(318): ra29.
|
15. |
Elbaz M, Nasser MW, Ravi J, et al. Modulation of the tumor microen-vironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol, 2015, 9(4): 906-919.
|
16. |
Maiello MR, Amelia D, Bevilacqua S, et al. EGFR and MEK blockade in triple negative breast cancer cells. J Cell Biochem, 2015 May 8. doi: 10.1002/jcb.25220.[Epubaheadofprint].
|
17. |
Ricciardi GR, Adamo B, Ieni A, et al. Androgen receptor(AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-Negative breast cancer(TNBC) patients. PLoS One, 2015, 10(6): e0128368.
|
18. |
Maeda T, Nakanishi Y, Hirotani Y, et al. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Med Mol Morphol, 2015, 2015 May 26.
|
19. |
Anestis A, Karamouzis MV, Dalagiorgou G, et al. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? Cancer Treat Rev, 2015, 41(6): 547-553.
|
20. |
Cuenca-López MD, Montero JC, Morales JC, et al. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer, 2014, 14: 302.
|
21. |
Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol, 2009, 20(5): 862-867.
|
22. |
Mancini P, Angeloni A, Risi E, et al. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers(Basel), 2014, 6(4): 2187-2223.
|
23. |
Vora HH, Patel NA, Thakore PM, et al. Immunohistochemical localization of wild-type EGFR, E746-A750 frame deletion in Exon 19, and L858R point mutation in Exon 21 in triple-negative breast cancer. Appl Immunohistochem Mol Morphol, 2015 Mar 16.
|
24. |
袁礼, 吴焕文, 任新瑜, 等.三阴乳腺癌与非三阴乳腺癌临床病理特征差异及与雌激素受体β和表皮生长因子受体表达的关系.协和医学杂志, 2015, (1): 1-8.
|
25. |
Montagna E, Cancello G, Bagnardi V, et al. Metronomic chemo-therapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer, 2012, 12(3): 207-214.
|
26. |
Sobande F, Dušek L, Matějková A, et al. EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number. Cesk Patol, 2015, 51(2): 80-86.
|
27. |
Sersh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with doeetaxel versus docetaxel alone: results of a prospective, randomized phaseⅢstudy. J Clin Oncol, 2012, 30(9): 921-929.
|
28. |
Crown JP, Diéras V, Staroslawska E, et al. PhaseⅢtrial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol, 2013, 31(23): 2870-2878.
|